{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:17:48Z","timestamp":1783725468696,"version":"3.55.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xops.2024.100548","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:04:13Z","timestamp":1715047453000},"page":"100548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-2396","authenticated-orcid":false,"given":"Ulrika","family":"Sj\u00f6bom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Hellqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhangir","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders K.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Gyllensten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatarina","family":"L\u00f6fqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.xops.2024.100548_bib1","first-page":"S89","article-title":"Update on blindness due to retinopathy of prematurity globally and in India","volume":"53","author":"Blencowe","year":"2016","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.xops.2024.100548_bib2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xops.2024.100548_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.xops.2024.100548_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjophthalmol-2016-308828","article-title":"The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review","volume":"101","author":"Kandasamy","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib5","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s40123-023-00744-7","article-title":"Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity","volume":"12","author":"Hartnett","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.xops.2024.100548_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270232","article-title":"A\u00a0systematic review and meta-analysis of preanalytical factors and methodological differences influencing the measurement of circulating vascular endothelial growth factor","volume":"17","author":"Sj\u00f6bom","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100548_bib7","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2024.100548_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2023","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.xops.2024.100548_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1202927","article-title":"Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis","volume":"11","author":"Alva","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.xops.2024.100548_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.884608","article-title":"Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity: a systematic review and meta-analysis","volume":"9","author":"Taher","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.xops.2024.100548_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3928\/23258160-20211124-01","article-title":"Aflibercept for retinopathy of prematurity: a systematic review and meta-analysis","volume":"52","author":"Chen","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2024.100548_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.xops.2024.100548_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100548_bib14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1055813","article-title":"Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: a systematic review and meta-analysis","volume":"11","author":"Diggikar","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.xops.2024.100548_bib16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.xops.2024.100548_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jrsm.1080","article-title":"Quality assessment of comparative diagnostic accuracy studies: our experience using a modified version of the QUADAS-2 tool","volume":"4","author":"Wade","year":"2013","journal-title":"Res Synth Meth"},{"key":"10.1016\/j.xops.2024.100548_bib19","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.xops.2024.100548_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.xops.2024.100548_bib21","series-title":"Meta-analysis with R","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.xops.2024.100548_bib22","series-title":"R: A Language and Environment for Statistical Computing","year":"2017"},{"key":"10.1016\/j.xops.2024.100548_bib23","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.xops.2024.100548_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.xops.2024.100548_bib25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res Synth Meth"},{"key":"10.1016\/j.xops.2024.100548_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.xops.2024.100548_bib27","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 10: analysing data and undertaking meta-analyses","author":"Deeks","year":"2023"},{"key":"10.1016\/j.xops.2024.100548_bib28","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.xops.2024.100548_bib29","series-title":"GRADE Handbook","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1016\/j.xops.2024.100548_bib30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1167\/iovs.15-18528","article-title":"Assessment of plasma cytokine profile changes in bevacizumab-treated retinopathy of prematurity infants","volume":"57","author":"Kong","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100548_bib31","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100548_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib33","first-page":"159","article-title":"The short-term effects of intravitreal injection of bevacizumab on the plasma levels of vascular endothelial growth factor, insulin-like growth factor-1, and growth parameters in infants with retinopathy of prematurity","volume":"32","author":"Sedaghat","year":"2020","journal-title":"J\u00a0Curr Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100548_bib35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100548_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic\u00a0vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2022.2887","article-title":"Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants","volume":"140","author":"Hartnett","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib39","first-page":"338","article-title":"Individual dose of intravitreal conbercept for efficacy in retinopathy of prematurity","author":"JIANG","year":"2021","journal-title":"Chin J Ocular Fundus Dis"},{"key":"10.1016\/j.xops.2024.100548_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1386207322666190325120244","article-title":"Can IL-33 and endocan be new markers for retinopathy of prematurity?","volume":"22","author":"Cakir","year":"2019","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.xops.2024.100548_bib41","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.xops.2024.100548_bib43","article-title":"Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity","volume":"10","author":"Cheng","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2024.100548_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/15513815.2020.1721625","article-title":"VEGF and Ang-2 levels in infants before and after laser treatment for retinopathy of prematurity","volume":"40","author":"Yang","year":"2021","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.xops.2024.100548_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib46","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bjophthalmol-2021-319131","article-title":"Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity","volume":"106","author":"Cheng","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib47","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100548_bib48","first-page":"466","article-title":"Effect of laser photocoagulation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity","volume":"18","author":"Yalin Imamoglu","year":"2014","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.xops.2024.100548_bib49","first-page":"194","article-title":"Potential contribution of mobilized circulating endothelial progenitor cells to development of retinal neovascularization in preterm infants with ROP","volume":"115","author":"Machali\u0144ska","year":"2013","journal-title":"Klin Oczna"},{"key":"10.1016\/j.xops.2024.100548_bib50","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10384-021-00895-9","article-title":"Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity","volume":"66","author":"Furuncuoglu","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib52","first-page":"1279","article-title":"Serum levels of insulin-like growth factor-1 and vascular endothelial growth factor in an infant with retinopathy of prematurity needing vitreous surgery","volume":"65","author":"Saito","year":"2011","journal-title":"Jpn J Clin Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib53","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.ophtha.2005.09.018","article-title":"Growth factor levels and ROP","volume":"112","author":"Villegas Becerril","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100548_bib54","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.xops.2024.100548_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2012-302724.0168","article-title":"168 serum veg F levels in preterm infants: effects of gestation and laser or bevacizumab therapy for retinopathy of prematurity","volume":"97","author":"Berrington","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.xops.2024.100548_bib56","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/15513815.2021.1948644","article-title":"The serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and insulin-like growth factor-1 in preterms with retinopathy of prematurity","volume":"41","author":"Aydo\u011fan","year":"2022","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.xops.2024.100548_bib57","first-page":"9","article-title":"Serum VEGF levels in infants at risk for developing retinopathy of prematurity","volume":"3","author":"Katsan","year":"2019","journal-title":"J Opthalmol (Ukraine)"},{"key":"10.1016\/j.xops.2024.100548_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079060","article-title":"Circulating endothelial progenitor cells decrease in infants with bronchopulmonary dysplasia and increase after inhaled nitric oxide","volume":"8","author":"Qi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100548_bib59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3928\/23258160-20131105-05","article-title":"Serum erythropoietin, insulin-like growth factor 1, and vascular endothelial growth factor in etiopathogenesis of retinopathy of prematurity","volume":"44","author":"Yenice","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2024.100548_bib60","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1167\/iovs.13-11837","article-title":"The relationship between cord blood cytokine levels and perinatal factors and retinopathy of prematurity: a gestational age-matched case-control study","volume":"54","author":"Woo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100548_bib61","first-page":"1982","article-title":"[Changes of serum vascular endothelial growth factor in newborn infants and its relationship with retinopathy of prematurity]","volume":"90","author":"Du","year":"2010","journal-title":"Zhonghua Yixue Zazhi"},{"key":"10.1016\/j.xops.2024.100548_bib62","first-page":"641","article-title":"[IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP)]","volume":"81","author":"Villegas-Becerril","year":"2006","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.xops.2024.100548_bib63","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jdn.10054","article-title":"Associations between VEGF isoforms and impending retinopathy of prematurity","volume":"80","author":"Movsas","year":"2020","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.xops.2024.100548_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/pr.2015.181","article-title":"Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity","volume":"79","author":"Hellgren","year":"2016","journal-title":"Pediatr Res"},{"key":"10.1016\/j.xops.2024.100548_bib65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.11622\/smedj.2013246","article-title":"Vascular endothelial growth factor and insulin-like growth factor-1 in preterm infants with retinopathy of prematurity","volume":"54","author":"Peirovifar","year":"2013","journal-title":"Singap Med J"},{"key":"10.1016\/j.xops.2024.100548_bib66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/pr.2016.241","article-title":"Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity","volume":"81","author":"Zepeda-Romero","year":"2017","journal-title":"Pediatr Res"},{"key":"10.1016\/j.xops.2024.100548_bib67","first-page":"251","article-title":"Variations of vascular endothelial growth factor and pigment epithelial-derived factor are related to retinopathy of prematurity in human babies","volume":"65","author":"Zhu","year":"2015","journal-title":"W\u00a0Indian Med J"},{"key":"10.1016\/j.xops.2024.100548_bib68","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00417-008-0865-9","article-title":"The\u00a0clinical role of vascular endothelial growth factor (VEGF)\u00a0system in the pathogenesis of retinopathy of prematurity","volume":"246","author":"Kwinta","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib69","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/archophthalmol.2010.221","article-title":"Circulating stem cell populations in preterm infants: implications for the development of retinopathy of prematurity","volume":"128","author":"Machalinska","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000512282","article-title":"Decreased platelet counts and serum levels of VEGF-A, PDGF-BB, and BDNF in extremely preterm infants developing severe ROP","volume":"118","author":"Hellgren","year":"2021","journal-title":"Neonatology"},{"key":"10.1016\/j.xops.2024.100548_bib71","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s10792-022-02576-z","article-title":"Systemic biomarkers of retinopathy of prematurity in preterm babies","volume":"43","author":"Sehgal","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib72","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1167\/iovs.17-21931","article-title":"Systemic inflammation-associated proteins and retinopathy of prematurity in infants born before the 28th week of gestation","volume":"58","author":"Holm","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100548_bib73","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1055\/s-0040-1701508","article-title":"Umbilical blood levels of IL-6 and TNF-\u03b1 as predictors of the central nervous system damage and retinopathy in preterm infants","volume":"38","author":"Bartkevi\u010dien\u0117","year":"2021","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.xops.2024.100548_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.9.13.14","article-title":"Cluster analysis of early postnatal biochemical markers may predict development of retinopathy of prematurity","volume":"9","author":"Markasz","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100548_bib75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12886-022-02565-x","article-title":"Correlation between apelin and VEGF levels in retinopathy of prematurity: a matched case\u2013control study","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib76","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1002\/jcb.26777","article-title":"Increased circulation mobilization of endothelial progenitor cells in preterm infants with retinopathy of prematurity","volume":"119","author":"Babaei","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.xops.2024.100548_bib77","first-page":"39","article-title":"Assessment of serum levels of angiogenic factors in dizygotic twin infants with and without retinopathy of prematurity","volume":"30","author":"Demir","year":"2013","journal-title":"J\u00a0Exp Clin Med"},{"key":"10.1016\/j.xops.2024.100548_bib78","first-page":"3","article-title":"The relationship between cytokines serum levels at postnatal 4-6 weeks and retinopathy of prematurity","volume":"22","author":"Yang","year":"2017","journal-title":"HK J Paediatr (new series)"},{"key":"10.1016\/j.xops.2024.100548_bib79","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.2007.128371","article-title":"VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity","volume":"92","author":"Pieh","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib80","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1080\/14767058.2017.1338261","article-title":"The lack of association between vascular endothelial growth factor and retinopathy of prematurity in an observational study","volume":"31","author":"Kandasamy","year":"2018","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.xops.2024.100548_bib81","article-title":"Role of serum levels of vascular endothelial growth factor and its receptor in retinopathy of prematurity","volume":"25","author":"Goswami","year":"2015","journal-title":"Iran J Pediatr (Engl Ed)"},{"key":"10.1016\/j.xops.2024.100548_bib82","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1111\/aos.13297","article-title":"Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity","volume":"95","author":"Feng","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib83","first-page":"377","article-title":"Plasma level of apelin as a promising factor for retinopathy of prematurity","author":"Feng","year":"202366","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.xops.2024.100548_bib84","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.xops.2024.100548_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109162","article-title":"Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data","volume":"222","author":"Lamminsalo","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2024.100548_bib86","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Robert","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.6.20","article-title":"Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100548_bib88","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4155\/bio-2018-0096","article-title":"Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit","volume":"11","author":"Sumner","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.xops.2024.100548_bib89","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100548_bib90","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/IAE.0b013e3181a3b848","article-title":"Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab","volume":"29","author":"Nonobe","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100548_bib91","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100548_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.62.3.2","article-title":"Tear fluid angiogenic factors: potential noninvasive biomarkers for retinopathy of prematurity screening in preterm infants","volume":"62","author":"Vinekar","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl A","key":"10.1016\/j.xops.2024.100548_bib93","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.ghir.2004.03.030","article-title":"Pathogenesis of retinopathy of prematurity","volume":"14","author":"Smith","year":"2004","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.xops.2024.100548_bib94","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100548_bib95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jrsm.1332","article-title":"Testing for funnel plot asymmetry of standardized mean differences","volume":"10","author":"Pustejovsky","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.xops.2024.100548_bib96","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1177\/0962280220910172","article-title":"Hybrid test for publication bias in meta-analysis","volume":"29","author":"Lin","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.xops.2024.100548_bib97","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.clinbiochem.2008.06.018","article-title":"QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of '-omics'-based technologies","volume":"41","author":"Lumbreras","year":"2008","journal-title":"Clin Biochem"},{"key":"10.1016\/j.xops.2024.100548_bib98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100548_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:02:28Z","timestamp":1732698148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666914524000848"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100548","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100548"}}